CU23511B6 - Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas - Google Patents

Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas

Info

Publication number
CU23511B6
CU23511B6 CU20060049A CU20060049A CU23511B6 CU 23511 B6 CU23511 B6 CU 23511B6 CU 20060049 A CU20060049 A CU 20060049A CU 20060049 A CU20060049 A CU 20060049A CU 23511 B6 CU23511 B6 CU 23511B6
Authority
CU
Cuba
Prior art keywords
cytostatics
cancer
combination
treatment
pharmaceutical combination
Prior art date
Application number
CU20060049A
Other languages
English (en)
Inventor
Daniel Eduardo Gomez
Daniel Fernando Alonso
Puente Aniel Sanchez
Ulloa Arielis Rodriguez
Gomez Yassel Ramos
Negrin Yasser Perera
Valdes Jeovanis Gil
Perez Vladimir Armando Besada
De Cossio Dorta Duque Jorge Fernandez
Nunez Lazaro Hiram Betancourt
Lopez Luis Javier Gonzalez
Rodriguez Silvio Ernesto Perea
Castro Boris Ernesto Acevedo
Serra Lila Rosa Castellanos
Original Assignee
Biorec B V
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40134932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU23511(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biorec B V, Ct Ingenieria Genetica Biotech filed Critical Biorec B V
Priority to CU20060049A priority Critical patent/CU23511B6/es
Priority to DO2007000040A priority patent/DOP2007000040A/es
Priority to ARP070100805A priority patent/AR059645A1/es
Priority to UY30175A priority patent/UY30175A1/es
Priority to KR1020087023587A priority patent/KR101454866B1/ko
Priority to MX2008011141A priority patent/MX2008011141A/es
Priority to PCT/CU2007/000010 priority patent/WO2007098719A1/es
Priority to CA2642943A priority patent/CA2642943C/en
Priority to US12/280,629 priority patent/US8871725B2/en
Priority to MYPI20083318A priority patent/MY150135A/en
Priority to RU2008138534/15A priority patent/RU2396974C2/ru
Priority to BRPI0708307-6A priority patent/BRPI0708307B1/pt
Priority to JP2008556646A priority patent/JP5733880B2/ja
Priority to AU2007219572A priority patent/AU2007219572B2/en
Priority to EP07711104A priority patent/EP1997506B8/en
Priority to HK09110055.2A priority patent/HK1132451B/xx
Priority to PE2007000215A priority patent/PE20081191A1/es
Priority to CN2007800152341A priority patent/CN101432012B/zh
Priority to PL07711104T priority patent/PL1997506T3/pl
Priority to ZA200807323A priority patent/ZA200807323B/xx
Priority to NO20084119A priority patent/NO341904B1/no
Publication of CU23511B6 publication Critical patent/CU23511B6/es
Priority to CY20131100142T priority patent/CY1114686T1/el
Priority to JP2013146681A priority patent/JP2013231065A/ja
Priority to US14/490,856 priority patent/US9226946B2/en
Priority to US14/518,242 priority patent/US9278118B2/en
Priority to CL2015001086A priority patent/CL2015001086A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona con una combinación farmacéutica que incluye un inhibidor de la fosforilación de la Caseína Kinasa 2 (denominado P15) y los citostáticos usados en la quimioterapia del cáncer los cuales son administrados simultáneos, separados o secuencialmente. Los citostáticos preferidos son los platinos, taxanos, alcaloides de la Vinca, 5-fluorouracilo, doxorubicina, ciclofosfamida, etoposide, mitomicina C, imatinib, iressa y el velcade (vortezomib). La sinergía entre el péptido P15 y los compuestos químicos anticancerígenos, hace que la concentración eficaz de cada citostáticos en la combinación sea entre uno y dos órdenes de magnitud menor que la correspondiente a los citostáticos sólos. Consecuentemente, la combinación descrita en la invención tiene una toxicidad mucho menor que la reportada para los citostáticos anticancerígenos lo cual representa una ventaja crucial para su uso en el tratamiento del cáncer. Adicionalmente, la combinación administrada de manera secuencial produce la quimiosensibilización de tumores refractarios a los citostáticos mencionados mediante el pretratamiento con el péptido P15.
CU20060049A 2006-02-28 2006-02-28 Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas CU23511B6 (es)

Priority Applications (26)

Application Number Priority Date Filing Date Title
CU20060049A CU23511B6 (es) 2006-02-28 2006-02-28 Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas
DO2007000040A DOP2007000040A (es) 2006-02-28 2007-02-23 Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas.
ARP070100805A AR059645A1 (es) 2006-02-28 2007-02-27 Combinacion farmaceutica para el tratamiento y/o quimiosensibilizacion de tumores refractarios a drogas anticancerigenas
UY30175A UY30175A1 (es) 2006-02-28 2007-02-27 Combinacion farmacéutica para el tratamiento y/o quimiosensibilizacion de tumores refractarios a drogas anticancerigenas
PL07711104T PL1997506T3 (pl) 2006-02-28 2007-02-28 Zastosowanie inhibitora CK2 do leczenia i uwrażliwienia na chemioterapię guzów opornych na leki przeciwnowotworowe
JP2008556646A JP5733880B2 (ja) 2006-02-28 2007-02-28 抗癌剤に不応な腫瘍の治療及び化学感作のためのｃｋ２阻害剤の使用
HK09110055.2A HK1132451B (en) 2006-02-28 2007-02-28 Use of ck2 inhibitor for the treatment and chemosensibilization of refractory tumors to anticancer drugs
PCT/CU2007/000010 WO2007098719A1 (es) 2006-02-28 2007-02-28 Combinación farmaceutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas
CA2642943A CA2642943C (en) 2006-02-28 2007-02-28 Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs
US12/280,629 US8871725B2 (en) 2006-02-28 2007-02-28 Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs
MYPI20083318A MY150135A (en) 2006-02-28 2007-02-28 Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs
RU2008138534/15A RU2396974C2 (ru) 2006-02-28 2007-02-28 Фармацевтическая комбинация для лечения и/или хемосенсибилизации опухолей, устойчивых к противораковым средствам
BRPI0708307-6A BRPI0708307B1 (pt) 2006-02-28 2007-02-28 Combinação farmacêutica para administração simultânea, separada ou sequencial, e, uso de um peptídeo como inibidor do sítio de fosforilação sobre os substratos de CK2 e um citostático farmaceuticamente aceitável
KR1020087023587A KR101454866B1 (ko) 2006-02-28 2007-02-28 항암 약물로에 대한 무반응성 종양의 치료 및 화학증감을 위한 ｃｋ2 저해제의 용도
AU2007219572A AU2007219572B2 (en) 2006-02-28 2007-02-28 Use of CK2 inhibitor for the treatment and chemosensibilization of refractory tumors to anticancer drugs
EP07711104A EP1997506B8 (en) 2006-02-28 2007-02-28 Use of ck2 inhibitor for the treatment and chemosensibilization of refractory tumors to anticancer drugs
MX2008011141A MX2008011141A (es) 2006-02-28 2007-02-28 Combinacion farmaceutica para el tratamiento y/o quimiosensibilizacion de tumores refractarios a drogas anticancerigenas.
PE2007000215A PE20081191A1 (es) 2006-02-28 2007-02-28 Combinacion farmaceutica para el tratamiento y/o quimiosensibilizacion de tumores refractarios a drogas anticancerigenas
CN2007800152341A CN101432012B (zh) 2006-02-28 2007-02-28 用于难治性肿瘤的治疗和/或难治性肿瘤对于抗癌药物的化学敏化的药物组合
ZA200807323A ZA200807323B (en) 2006-02-28 2008-08-23 Use of CK2 inhibitor for the treatment and chemosensibilization of refractory tumors to anticancer drugs
NO20084119A NO341904B1 (no) 2006-02-28 2008-09-29 Farmasøytisk kombinasjon for simultan, separat eller sekvensiell administrasjon
CY20131100142T CY1114686T1 (el) 2006-02-28 2013-02-15 Χρηση toy ck2 αναστολεα για την θεραπεια και χημειοευαισθητοποιηση των ανθεκτικων σε αντικαρκινικα φαρμακα ογκων
JP2013146681A JP2013231065A (ja) 2006-02-28 2013-07-12 抗癌剤に不応な腫瘍の治療及び化学感作のためのｃｋ２阻害剤の使用
US14/490,856 US9226946B2 (en) 2006-02-28 2014-09-19 Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs
US14/518,242 US9278118B2 (en) 2006-02-28 2014-10-20 Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs
CL2015001086A CL2015001086A1 (es) 2006-02-28 2015-04-24 Combinación farmacéutica para el tratamiento y/o quimiosensibilizacion de tumores refractarios a drogas anticancerigenas

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20060049A CU23511B6 (es) 2006-02-28 2006-02-28 Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas

Publications (1)

Publication Number Publication Date
CU23511B6 true CU23511B6 (es) 2010-04-13

Family

ID=40134932

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20060049A CU23511B6 (es) 2006-02-28 2006-02-28 Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas

Country Status (22)

Country Link
US (3) US8871725B2 (es)
EP (1) EP1997506B8 (es)
JP (2) JP5733880B2 (es)
KR (1) KR101454866B1 (es)
CN (1) CN101432012B (es)
AR (1) AR059645A1 (es)
AU (1) AU2007219572B2 (es)
BR (1) BRPI0708307B1 (es)
CA (1) CA2642943C (es)
CL (1) CL2015001086A1 (es)
CU (1) CU23511B6 (es)
CY (1) CY1114686T1 (es)
DO (1) DOP2007000040A (es)
MX (1) MX2008011141A (es)
MY (1) MY150135A (es)
NO (1) NO341904B1 (es)
PE (1) PE20081191A1 (es)
PL (1) PL1997506T3 (es)
RU (1) RU2396974C2 (es)
UY (1) UY30175A1 (es)
WO (1) WO2007098719A1 (es)
ZA (1) ZA200807323B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23511B6 (es) * 2006-02-28 2010-04-13 Biorec B V Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
US20100173013A1 (en) * 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
CA3116731A1 (en) 2018-10-19 2020-04-23 Senhwa Biosciences, Inc. Combinations for immune-modulation in cancer treatment
CN109875998B (zh) * 2019-01-24 2021-09-03 武汉大学 酰胺类生物碱在制备肿瘤化疗药物增敏剂中的应用及抗肿瘤药物组合物
CN110448699B (zh) * 2019-06-12 2022-03-11 天津医科大学 包含功能性多肽修饰七甲川花菁素类染料的肿瘤细胞核靶向载药纳米粒子及制备方法
CU20200103A7 (es) * 2020-12-18 2022-07-08 Ct Ingenieria Genetica Biotecnologia Péptido sintético para la inducción de inmunidad antitumoral y antiviral
CN114712377B (zh) * 2022-04-26 2023-08-15 江苏师范大学 断血流皂苷a在制造药物中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1977749A1 (en) * 1996-10-15 2008-10-08 G.D. Searle LLC Use of cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
CU23225A1 (es) 2001-12-20 2007-08-30 Ct Ingenieria Genetica Biotech PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES
AU2003217961B2 (en) * 2002-03-08 2008-02-28 Signal Pharmaceuticals, Llc Combination therapy for treating, preventing or managing proliferative disorders and cancers
US20060014987A1 (en) * 2003-07-07 2006-01-19 Lan Huang Synthesis of beta-elemene, intermediates thereto, analogues and uses thereof
EP1691809A1 (en) * 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
ATE447957T1 (de) 2003-12-09 2009-11-15 Us Gov Health & Human Serv Verfahren zur unterdrückung einer immunantwort oder zur behandlung von proliferativen erkrankungen
TW200538149A (en) * 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
CU23511B6 (es) * 2006-02-28 2010-04-13 Biorec B V Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas

Also Published As

Publication number Publication date
RU2396974C2 (ru) 2010-08-20
UY30175A1 (es) 2008-01-31
DOP2007000040A (es) 2007-09-30
PE20081191A1 (es) 2008-09-24
US20090130228A1 (en) 2009-05-21
NO20084119L (no) 2008-11-25
US9226946B2 (en) 2016-01-05
CL2015001086A1 (es) 2016-05-13
CA2642943C (en) 2013-07-23
US8871725B2 (en) 2014-10-28
US20150030700A1 (en) 2015-01-29
AU2007219572A1 (en) 2007-09-07
HK1132451A1 (en) 2010-02-26
JP5733880B2 (ja) 2015-06-10
RU2008138534A (ru) 2010-04-10
MX2008011141A (es) 2009-01-26
CN101432012A (zh) 2009-05-13
US20150111832A1 (en) 2015-04-23
CN101432012B (zh) 2013-01-02
PL1997506T3 (pl) 2013-04-30
BRPI0708307B8 (es) 2021-05-25
EP1997506B8 (en) 2013-02-20
CY1114686T1 (el) 2016-10-05
JP2013231065A (ja) 2013-11-14
EP1997506A1 (en) 2008-12-03
NO341904B1 (no) 2018-02-19
KR20090030251A (ko) 2009-03-24
MY150135A (en) 2013-11-29
EP1997506B1 (en) 2012-12-05
AR059645A1 (es) 2008-04-16
WO2007098719A1 (es) 2007-09-07
BRPI0708307B1 (pt) 2019-07-23
US9278118B2 (en) 2016-03-08
BRPI0708307A2 (pt) 2011-05-24
KR101454866B1 (ko) 2014-11-04
ZA200807323B (en) 2009-05-27
CA2642943A1 (en) 2007-09-07
AU2007219572B2 (en) 2012-07-05
JP2009528306A (ja) 2009-08-06

Similar Documents

Publication Publication Date Title
DOP2007000040A (es) Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas.
DK1951729T3 (da) Oxygenbundne pyrimidinderivater
CY1111065T1 (el) Φαρμακευτικη συνθεση που περιεχει μια ωμεγα-καρβοξυαρυλ υποκατεστημενη διφαινυλ ουρια για τη θεραπευτικη αντιμετωπιση του καρκινου
PE20070723A1 (es) Imidazopirazinas como inhibidores de quinasas dependientes de ciclina
CL2007001994A1 (es) Compuestos derivados de heterociclos nitrogenados que comprenden fosfonato y fosfinato, activadores de la glucocinasa; composicion farmaceutica que los comprende; y uso de los compuestos en el tratamiento de la diabetes, hiperglicemia, hiperinsulinemia, cancer, demencia, obesidad, entre otras.
BR112022009563A2 (pt) Compostos de pirrolotriazina atuando como inibidor de mnk
CL2011001536A1 (es) Compuestos derivados de pirimidin-2-il-1h-indol, inhibidores de la proteina quinasa atr; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento del cancer.
UY30559A1 (es) Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones
BRPI0607809A2 (pt) uso de uma composição compreendendo nanopartìculas, composição e kit
CL2008002243A1 (es) Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
CL2008001743A1 (es) Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende.
NO20080629L (no) Tiazolderivater som AMPK-aktiverere
CL2008003873A1 (es) Compuestos derivados de benzofuropirimidinona sustituidos, inhibidores de proteinas quinasas; composicion farmaceutica que comprende a uno de los compuestos; metodo para inhibir in vitro proteinas quinasa (pim, cdc7,ck2); y uso de los compuestos en la preparacion de medicamentos para el tratamiento del cancer
CL2013003160A1 (es) Compuestos derivados de 4h-cromen-4-ona moduladores de la proteina cinasa pi3k; compuestos intermediarios; composicion farmaceutica que los comprende; y utiles en el tratamiento del cancer, agentes antinflamatorios, inmunosupresores, esteroides, analgesicos, leucemia, entre otros.
CL2012003680A1 (es) Compuestos derivados de (1,8) naftiridinas 2,4 diaril sustituidas inhibidores de quinasas; su procedimiento de obtencion; composicion farmaceutica; y su uso para el tratamiento y/o prevencion de cancer, tumor, tumores malignos, entre otros; kit farmaceutico.
GT200600046A (es) Terapia de combinacion
CL2008001745A1 (es) Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso de los compuestos como inhibidores de la proteína quinasa en el tratamiento del cáncer.
UY27943A1 (es) Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos
AR056801A1 (es) Terapia combinada anti- proliferativa con determinados agentes quimioterapeuticos basados en platino e inhibidores de egfr o analogos de pirimidina
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
AR057148A1 (es) Combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
AR085399A1 (es) Combinacion antitumoral que comprende cabazitaxel y cisplatino
CU23431B6 (es) Método para la inhibición de la proliferación de células tumorales y el tratamiento del cáncer
ATE492286T1 (de) Poly-epitop peptid abgeleitet aus der thymidylat- synthase mit immunologischer und anti-tumor aktivität

Legal Events

Date Code Title Description
FG Grant of patent